FDA
-
-
-
-
-
-
-
FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
-
-
-
-
-
-
-
AMGEN to present Repatha trial data at heart association meeting
-
-
-
-
-
-
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
-
-
-
-
-
-
FDA expands AMGEN's Repatha approval for cardiovascular risk reduction
-
-
-
-
-
-
-
Amgen (AMGN) reports full results from Part 1 of the Phase 2 study of MariTide
-
-
-
-
-
-
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
-
-
-
-
-
-
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

